Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04504331
Title Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Stanford University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford University Stanford California 94304 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field